December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Inhibition of Corneal Neovacularization by Pioglitazone, a Peroxisome Proliferator-Activated Receptor- Ligand
Author Affiliations & Notes
  • MA Sarayba
    Ophthalmology
    University of California Irvine Irvine CA
  • L Li
    Ophthalmology
    University of California Irvine Irvine CA
  • T Tungsiripat
    Ophthalmology
    University of California Irvine Irvine CA
  • NH Liu
    Ophthalmology
    University of California Irvine Irvine CA
  • PM Sweet
    Ophthalmology
    University of California Irvine Irvine CA
  • JA Sanchez
    Ophthalmology
    University of California Irvine Irvine CA
  • AJ Patel
    Ophthalmology
    University of California Irvine Irvine CA
  • KE Osann
    Medicine
    University of California Irvine Irvine CA
  • HA Pershadsingh
    Medicine Kern County Medical Center Fresno CA
  • RS Chuck
    Ophthalmology
    University of California Irvine Irvine CA
  • Footnotes
    Commercial Relationships   M.A. Sarayba, None; L. Li, None; T. Tungsiripat, None; N.H. Liu, None; P.M. Sweet, None; J.A. Sanchez, None; A.J. Patel, None; K.E. Osann, None; H.A. Pershadsingh, None; R.S. Chuck, None. Grant Identification: Support: The Kern Medical Center, Community & Medical Education Research Foundation
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1745. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      MA Sarayba, L Li, T Tungsiripat, NH Liu, PM Sweet, JA Sanchez, AJ Patel, KE Osann, HA Pershadsingh, RS Chuck; Inhibition of Corneal Neovacularization by Pioglitazone, a Peroxisome Proliferator-Activated Receptor- Ligand . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1745.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the efficacy of the peroxisome proliferator-activated receptor γ agonist, pioglitazone, in inhibiting corneal neovascularization. Methods: Twenty-six adult male Sprague-Dawley rats were randomly divided into 3 groups. Each group received intrastromal polymer micropellets containing one of the following: Group 1, no active ingredient (n=10); Group 2, vascular endothelial growth factor (VEGF) (n=7); Group 3, VEGF and pioglitazone, n=9). The micropellets were implanted into a 50% depth trapezoidal corneal lamellar micropocket adjacent to the limbus. Neovascularization was evaluated 7 days after pellet implantation. After systemic India ink injection, digital photographs of the eyes were taken. The area and density of neovascularization were measured using imaging software (Scion Image for Windows, Scion Corp., Frederick, MD). Results: Microscopic observation confirmed the presence of the pellets in all eyes 7 days after implantation. Mean area of neovascularization was 0.43 + 0.18 mm2 for Group 1, 2.87 + 0.48 mm2 for Group 2 and 2.10 + 0.22 mm2 for Group 3. Statistical analysis showed significant differences between Groups 1 & 2 and Groups 1 & 3. There was no significant difference between Groups 2 & 3. Mean density of neovascularization was 2.16 + 0.66 for Group 1, 27.14 + 2.93 for Group 2 and 12.02 + 2.24 for Group 3. All comparisons between groups were statistically significant (P < .01). Conclusion: Pioglitazone is effective in decreasing the density of angiogenesis in a VEGF-induced neovascular rat cornea model. It is a promising drug for the treatment of ocular neovascularization.

Keywords: 514 pharmacology • 614 vascular cells • 440 inhibitory receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×